AUA

Shorts

Jenny N. Guo, MD, on key BPH takeaways from AUA 2026
0:36
Jenny N. Guo, MD, on key BPH takeaways from AUA 2026
5 months ago
by
Jenny N. Guo, MD
Kari A.O. Tikkinen, MD, PhD, discusses tranexamic acid in urology
0:33
Kari A.O. Tikkinen, MD, PhD, discusses tranexamic acid in urology
6 months ago
by
Kari A.O. Tikkinen, MD, PhD
Nicole L. Miller, MD, FACS, on advances in evaluating and treating LUTS
1:38
Nicole L. Miller, MD, FACS, on advances in evaluating and treating LUTS
6 months ago
by
Nicole L. Miller, MD, FACS
Catherine A. Matthews, MD, FACS, shares takeaways from the INTIBIA Pivotal Trial
0:32
Catherine A. Matthews, MD, FACS, shares takeaways from the INTIBIA Pivotal Trial
6 months ago
by
Catherine A. Matthews, MD, FACOG, FACS, FPMRS
Michael S. Cookson, MD, on darolutamide’s safety profile
0:22
Michael S. Cookson, MD, on darolutamide’s safety profile
6 months ago
by
Michael S. Cookson, MD, MMHC, FACS
Jonathan D. Harper, MD, on increasing fluid intake to prevent recurrent stones
0:41
Jonathan D. Harper, MD, on increasing fluid intake to prevent recurrent stones
6 months ago
by
Jonathan D. Harper, MD
Nima Almassi, MD, on shared decision-making around bladder-preserving treatment options
0:57
Nima Almassi, MD, on shared decision-making around bladder-preserving treatment options
6 months ago
by
Nima Almassi, MD
Kathryn H. Gessner, MD, PhD, on the most exciting current developments in bladder cancer
0:49
Kathryn H. Gessner, MD, PhD, on the most exciting current developments in bladder cancer
6 months ago
by
Kate Gessner, MD, PhD
Joshua J. Meeks, MD, PhD, on the need for recombinant BCG
0:18
Joshua J. Meeks, MD, PhD, on the need for recombinant BCG
6 months ago
by
Joshua J. Meeks, MD, PhD
Nicole L. Miller, MD, FACS, on what she tells patients after BPH treatment failure
0:39
Nicole L. Miller, MD, FACS, on what she tells patients after BPH treatment failure
6 months ago
by
Nicole L. Miller, MD, FACS

Latest Content

The phase 1/2 ResQ133A-NMIBC trial (NCT06800963) is evaluating intravesical recombinant BCG in patients with BCG-naïve high-risk NMIBC across US sites, with safety as the primary end point and complete response and disease-free survival as secondary end points, building on European data showing 50% response rates and no dose-limiting toxicities in BCG-unresponsive disease.

In this interview, Kari A.O. Tikkinen, MD, PhD, explains why effective nocturia management in geriatric patients requires systematic phenotyping across 4 primary subtypes—nocturnal polyuria, reduced bladder capacity, bladder outlet obstruction, and sleep-driven causes—rather than empiric pharmacologic treatment, with many cases requiring interdisciplinary referral rather than urologic intervention alone.